TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03571035

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mandibular movements recordings by a mono vision system
Description: To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
Study: NCT03906864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Pathway
Description: The intervention group had the following as part of the integrated care pathway:~1. Medical assessment on admission for risk factors for falls.~2. A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~3. Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~4. Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~5. A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers.
Study: NCT01861392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sensorio-motor training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sensorio-motor training
Study: NCT02787304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Description: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Description: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Description: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00653874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiliChek (jaundice assessment)
Description: assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiliChek (jaundice assessment)
Description: assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB)
Description: transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical asessment of bilirubin (CaB)
Description: Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
Study: NCT03042845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tiger cardiac catheter
Description: Tiger cardiac catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Judkins 3.5L/4R cardiac catheters
Description: Judkins 3.5L/4R cardiac catheters
Study: NCT04041622

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endoscopy and biopsy
Description: Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
Study: NCT03225365

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and biopsy sampling
Description: Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood and biopsy sampling
Description: Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression.
Study: NCT01118078

Intervention type: GENETIC
Intervention: DNA methylation analysis
Description: Undergo DNA methylation analysis

Intervention type: GENETIC
Intervention: gene expression analysis
Description: Undergo gene expression analysis

Intervention type: GENETIC
Intervention: microarray analysis
Description: Undergo microarray analysis

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: Undergo RT-PCR

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study: NCT02442609

Intervention type: OTHER
Intervention: questionaire
Description: questionaire before surgery
Study: NCT02084524

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Malnutrition screening and perioperative nutritional support
Description: * Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines
Study: NCT05297357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet weaning scheme
Description: Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
Study: NCT02977351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Study: NCT01932489

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy of a metastatic lesion.
Study: NCT01389739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention to improve continuity of care
Description: Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
Study: NCT00830219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole HCl 0.25 mg Tablets
Description: 1 x 0.25 mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Requip® 0.25 mg Tablets
Description: 1 x 0.25 mg, single dose fed
Study: NCT03913234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib, Trastuzumab, Letrozole
Description: Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
Study: NCT02815371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle Acupuncture
Description: See above

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: See above

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture
Description: See above
Study: NCT01928771

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 44 inclusive.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 44 inclusive.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 44 inclusive.
Study: NCT00730184

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: potassium bicarbonate
Description: 90 mmol/d given as 4 tablets after each meal, with a full glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Description: Given as 4 tablets after each meal, with a full glass of water
Study: NCT00427934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: 300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc Placebo
Description: Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
Study: NCT03053739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 20mg and Bosentan 62.5mg
Description: Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil 20mg and Placebo
Description: Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
Study: NCT00634517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armstrong Albuterol Sulfate Inhalation Aerosol
Description: Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate Inhalation Aerosol
Description: Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
Study: NCT04635839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose of Unfractionated Heparin
Description: 5,000 units subcutaneous unfractionated heparin every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gestational Age-Based Dose of Unfractionated Heparin
Description: * First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (\> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours
Study: NCT01419457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 800 mg BID for Day 1 + 400 mg BID for Day 2-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 800 mg Single Dose
Study: NCT03618823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study: NCT03389165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable hip assist robot
Description: All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
Study: NCT04211584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transradial interventions
Description: percutaneous coronary interventions in stable patients - diagnostic and treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transradial interventions
Description: percutaneous coronary interventions in stable patients - diagnostic and treatment
Study: NCT02532400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy
Description: Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
Study: NCT02452047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem+Cilastatin/Relebactam
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
Study: NCT03956823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan
Description: Telmisartan group: telmisartan 80 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine group: amlodipine 5 mg once a day
Study: NCT01812551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
Study: NCT02625727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid combined corticosteroid
Description: compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
Study: NCT01242358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Capnographic monitoring

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring
Study: NCT01246739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Description: Adrenalectomy (open or laparoscopic)
Study: NCT04151797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Description: The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* Data collection on comorbidities, medication and laboratory results.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* A detailed feedback to the geriatrician.~* A written report addressed to the attending physician
Study: NCT01684332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam
Study: NCT02452047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem+Cilastatin/Relebactam
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistimethate sodium (CMS)
Description: Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem+Cilastatin
Description: Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to CMS
Description: Placebo to CMS IV infusion once every 12 hours
Study: NCT00927407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malathion gel 0.5%
Description: Malathion gel 0.5% applied to the scalp for 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malathion lotion 0.5%
Description: Malathion lotion 0.5% applied to scalp for 12 hours
Study: NCT00499122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV 002
Study: NCT01657617

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost Stereotactic Body Radiation Therapy
Description: The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy.
Study: NCT03057574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa
Description: Patients must be prescribed Follitropin Alfa (Gonapure®)
Study: NCT04609137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early drain removal
Description: Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard drain removal
Description: Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection
Study: NCT04597567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal removal
Description: Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
Study: NCT01679743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN 1005
Description: GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN 1005
Description: GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.